On October 18, 2023 Patrys reported that data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of high grade glioma will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Brain Cancer in Minneapolis, Minnesota (Press release, Patrys, OCT 18, 2023, View Source [SID1234636117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster, titled "A novel lupus-associated antibody that inhibits the growth of aggressive high-grade glioma orthotopic xenografts and enhances radiotherapy via a unique mechanism" describes research conducted by Professor Terrance Johns from the Telethon Kids Cancer Centre in Perth confirming the single agent activity of both PAT-DX1 and PAT-DX3 in animal models of high grade glioma, as well as the significant survival benefits from combining PAT-DX1 with a therapeutic dose of radiation.

Professor Terrence Johns said:

"I am excited to present our findings with PAT-DX1 and PAT-DX3 at the AACR (Free AACR Whitepaper) Special Conference in Cancer Research: Brain Cancer. Through my partnership with Patrys we have demonstrated both antibodies reach and inhibit the growth of intracranial brain cancers in rodent models. Significantly, we have shown that PAT-DX1 dramatically enhances the activity of radiotherapy, which is the standard of care for many forms of brain cancer."